Composition
Tab: Ceritinib 150 mg
Indications & Dosage
Treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer previously treated with crizotinib: Adult: 750 mg once daily, dose should be taken at the same time every day, temporary dose interruption or dose reduction may be required based on tolerability; consult product literature; discontinue treatment if patient unable to tolerate at least 300 mg daily.
Contraindications
Congenital long QT syndrome
Precautions
Severe renal or hepatic impairment, monitor LFTs, diabetes mellitus, history or susceptibility to QT-interval prolongation, risk for ventricular tachyarrhythmias, risk factors include pre-existing bradycardia, other relevant pre-existing cardiac disease or electrolyte disturbances; manufacturer advises to monitor ECG and electrolytes periodically, risk interstitial lung disease Manufacturer advises monitor patients who exhibit pulmonary symptoms and consider dose reduction or discontinuation of treatment
Interactions
Aliskiren, Antacids, Antiarrhythmics, Antiepileptics, Antifungals, azoles, non-sedating antihistamines, Aprepitant, Calcium channel blockers, ciclosporin, Cobicistat, colchicine, Coumarins (warfarin), Crizotinib, dabigatran, digoxin, edoxaban, Enzalutamide, ergotamine, everolimus, Grapefruit juice (avoid), H2 receptor antagonists, HIV-protease inhibitors, Idelalisib, Imatinib, Lapatinib, loperamide, Macrolides, Netupitant, Nilotinib, NSAIDs, Opioids, pimozide, Proton pump inhibitors, Ranolazine, Rifampicin, sirolimus. St Johns Wort, sulfonylureas (glimepiride). Tacrolimus,Taxanes, topotecan.
Pregnancy
Avoid unless essential
Lactation
Contraindicated. Discontinue breast-feeding.
Side Effects
Abdominal pain, anaemia, bradycardia, constipation, decreased appetite, diarrhea, dyspepsia, dysphagia, fatigue, gastro-oesophageal reflux disease, hyperglycaemia, hypophosphataemia, nausea, pericarditis, pneumonitis, QT-interval prolongation, rash, renal failure, renal impairment, visual disorders, vomiting. Rare: Hepatotoxicity, pancreatitis, interstitial lung disease